BRPI0916092A2 - "isoformas específicas de anticorpos anti-her4" - Google Patents

"isoformas específicas de anticorpos anti-her4"

Info

Publication number: BRPI0916092A2
Authority: BR; Brazil
Prior art keywords: specific anti; her4 antibody; antibody isoforms; isoforms; her4
Prior art date: 2008-11-25

Application number

BRPI0916092A

Other languages

English (en)

Inventor

Klaus Elenius

Maija Hollmen

Mark X Sliwkowski

Original Assignee

Genentech Inc

Univ Turku

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-25

Filing date

2009-11-24

Publication date

2015-11-17

2009-11-24 Application filed by Genentech Inc, Univ Turku filed Critical Genentech Inc

2015-11-17 Publication of BRPI0916092A2 publication Critical patent/BRPI0916092A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

BRPI0916092A 2008-11-25 2009-11-24 "isoformas específicas de anticorpos anti-her4" BRPI0916092A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11790308P	2008-11-25	2008-11-25
PCT/US2009/065712 WO2010068437A1 (en)	2008-11-25	2009-11-24	Isoform specific anti-her4 antibodies

Publications (1)

Publication Number	Publication Date
BRPI0916092A2 true BRPI0916092A2 (pt)	2015-11-17

Family

ID=42021645

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0916092A BRPI0916092A2 (pt)	2008-11-25	2009-11-24	"isoformas específicas de anticorpos anti-her4"

Country Status (15)

Country	Link
US (2)	US20110293614A1 (pt)
EP (1)	EP2365987B1 (pt)
JP (1)	JP5894436B2 (pt)
KR (1)	KR101789338B1 (pt)
CN (2)	CN102725310A (pt)
AU (1)	AU2009324939B2 (pt)
BR (1)	BRPI0916092A2 (pt)
CA (1)	CA2744512C (pt)
DK (1)	DK2365987T3 (pt)
ES (1)	ES2528929T3 (pt)
IL (1)	IL212900A0 (pt)
MX (1)	MX2011005382A (pt)
PL (1)	PL2365987T3 (pt)
SI (1)	SI2365987T1 (pt)
WO (1)	WO2010068437A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102725310A (zh)	2008-11-25	2012-10-10	健泰科生物技术公司	同等型特异性抗her4抗体
US10083108B1 (en) *	2017-12-18	2018-09-25	Clover Network, Inc.	Automated stack-based computerized application crawler
CN112753956A (zh) *	2021-01-20	2021-05-07	重庆周师兄餐饮文化有限公司	一种腰片的加工方法
CN113999228B (zh) *	2021-11-08	2022-11-04	南京卓康医药科技有限公司	一种他达拉非的合成方法
CN119823274A (zh) *	2023-10-12	2025-04-15	徕特康(苏州)生物制药有限公司	抗her4抗体及其制备方法和用途
CN119823275A (zh) *	2023-10-12	2025-04-15	徕特康(苏州)生物制药有限公司	抗her4抗体及其制备方法和用途
CN119823276A (zh) *	2023-10-12	2025-04-15	徕特康(苏州)生物制药有限公司	抗her4抗体及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
EP1005870B1 (en)	1992-11-13	2009-01-21	Biogen Idec Inc.	Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2103323A1 (en)	1992-11-24	1994-05-25	Gregory D. Plowman	Her4 human receptor tyrosine kinase
US5811098A (en) *	1992-11-24	1998-09-22	Bristol-Myers Squibb Company	Antibodies to HER4, human receptor tyrosine kinase
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
EP0912734B1 (en)	1996-07-12	2010-11-03	Genentech, Inc.	Chimeric heteromultimer adhesins
US6121415A (en)	1997-07-09	2000-09-19	Genentech, Inc.	ErbB4 receptor-specific neuregolin related ligands and uses therefor
AU9805398A (en) *	1997-10-15	1999-05-03	Children's Medical Center Corporation	Novel human egf receptors and use thereof
US20020119148A1 (en)	2000-09-01	2002-08-29	Gerritsen Mary E.	ErbB4 antagonists
CN102725310A (zh)	2008-11-25	2012-10-10	健泰科生物技术公司	同等型特异性抗her4抗体

2009
- 2009-11-24 CN CN2009801546763A patent/CN102725310A/zh active Pending
- 2009-11-24 DK DK09760430.0T patent/DK2365987T3/en active
- 2009-11-24 ES ES09760430.0T patent/ES2528929T3/es active Active
- 2009-11-24 BR BRPI0916092A patent/BRPI0916092A2/pt not_active Application Discontinuation
- 2009-11-24 PL PL09760430T patent/PL2365987T3/pl unknown
- 2009-11-24 AU AU2009324939A patent/AU2009324939B2/en active Active
- 2009-11-24 KR KR1020117014616A patent/KR101789338B1/ko active Active
- 2009-11-24 JP JP2011537710A patent/JP5894436B2/ja active Active
- 2009-11-24 WO PCT/US2009/065712 patent/WO2010068437A1/en not_active Ceased
- 2009-11-24 SI SI200931133T patent/SI2365987T1/sl unknown
- 2009-11-24 US US13/130,789 patent/US20110293614A1/en not_active Abandoned
- 2009-11-24 EP EP09760430.0A patent/EP2365987B1/en active Active
- 2009-11-24 CA CA2744512A patent/CA2744512C/en active Active
- 2009-11-24 CN CN201710670250.XA patent/CN109608545A/zh active Pending
- 2009-11-24 MX MX2011005382A patent/MX2011005382A/es active IP Right Grant
2011
- 2011-05-16 IL IL212900A patent/IL212900A0/en unknown
2015
- 2015-11-19 US US14/946,318 patent/US9963517B2/en active Active

Also Published As

Publication number	Publication date
JP2012509896A (ja)	2012-04-26
US20110293614A1 (en)	2011-12-01
IL212900A0 (en)	2011-07-31
PL2365987T3 (pl)	2015-04-30
SI2365987T1 (sl)	2015-03-31
CA2744512C (en)	2018-05-15
AU2009324939A1 (en)	2010-06-17
ES2528929T3 (es)	2015-02-13
KR101789338B1 (ko)	2017-10-23
AU2009324939B2 (en)	2015-07-09
MX2011005382A (es)	2011-07-20
CA2744512A1 (en)	2010-06-17
KR20110098756A (ko)	2011-09-01
EP2365987A1 (en)	2011-09-21
US20160075798A1 (en)	2016-03-17
US9963517B2 (en)	2018-05-08
WO2010068437A1 (en)	2010-06-17
CN109608545A (zh)	2019-04-12
EP2365987B1 (en)	2014-11-12
CN102725310A (zh)	2012-10-10
DK2365987T3 (en)	2015-01-12
JP5894436B2 (ja)	2016-03-30

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-13	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2019-09-17	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 10A ANUIDADE.
2019-11-26	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements

Publication	Publication Date	Title
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0910229A2 (pt)	2015-09-01	Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
BRPI0814252A2 (pt)	2015-04-14	Formulações de anticorpo
PT2889310T (pt)	2018-03-26	Formulações de anticorpo
PL3059246T3 (pl)	2018-11-30	Zmodyfikowany region stały przeciwciała
BRPI0913806A2 (pt)	2015-10-20	"composição"
BRPI0820819A2 (pt)	2015-06-16	Formulação de anticorpos
EP2211903A4 (en)	2011-07-06	CLL-1 ANTIBODY
BR112012012872A2 (pt)	2017-10-10	"pirrolindinas de espiroindolinona"
BRPI0914533A2 (pt)	2015-12-15	"métodos"
BRPI0922904A2 (pt)	2018-05-29	"compostos"
EP2150167A4 (en)	2012-09-05	SEMI-DISPOSABLE ENDOSCOPE
EP2254911A4 (en)	2011-10-19	HUMANIZED ANTI-C5aR ANTIBODIES
EP2241578A4 (en)	2012-09-12	Anti-cldn6 antibody
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
EP2172483A4 (en)	2010-08-04	ANTI-MUC17 ANTIBODY
EP2262831A4 (en)	2012-07-25	ANTI-properdin antibody
EP2245315A4 (en)	2012-10-24	O-HEAD DESIGN
EP2207803A4 (en)	2010-11-24	Cd9-specific human antibodies
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
MA30948B1 (fr)	2009-12-01	MYRTILLE NOMME " DrisBlueThree "
MA30949B1 (fr)	2009-12-01	MYRTILLE NOMME "DrisBlueTwo"
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
EP2212431A4 (en)	2011-05-11	ANTIBODY AGAINST IREM-1